(Q34122822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Manuel Hidalgo

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

I Garrido-Laguna

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Uson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Angenendt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

W W Ma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M C Villaroel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Zhao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

N V Rajeshkumar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Jimeno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

R Donehower

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

C Iacobuzio-Donahue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Barrett

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M A Rudek

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

B Rubio-Viqueira

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

D Laheru

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

27 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

649-655

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605819

8 February 2020

exact match

0 references

cites work

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Targeting the mTOR signaling network for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Exploiting the PI3K/AKT pathway for cancer drug discovery

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

FRA3B and other common fragile sites: the weakest links

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605819

Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2938261

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

28 October 2018

1 reference

12 December 2020

Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines

1 reference

12 December 2020

An in vivo platform for translational drug development in pancreatic cancer

1 reference

12 December 2020

Targeting mTOR for cancer treatment

1 reference

12 December 2020

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605819

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

8 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20664591%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference